Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Runny Nose Article
This is a selection made from among articles on Drug Treatment Runny Nose. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Alcohol Rehab Treatment
By Damian Murphy
Similar to other illnesses, alcohol addiction can be overcome with increased research efforts, prevention, and proper alcohol addiction treatment.
By providing more people with access to expert alcoholic treatment, the costly drain on society and the physical, psychological, and financial barriers that alcohol addiction places on families can be considerably diminished.
If truth be told, research studies display strong data that effectual alcohol dependency treatment programs and alcohol addiction prevention efforts lead to irrefutable reductions in cancer, hearth disease, child abuse, strokes, traffic fatalities, crime, unwanted pregnancy, HIV, and child abuse.
Special techniques exist for treating alcohol dependency withdrawal. Whereas some of these therapies use medications, scores of, alternatives, do not. Fascinatingly, according to current research findings, the safest way to treat mild withdrawal symptoms is without drugs.
Such non-drug detoxification approaches use wide-extending social support and screening all through the whole withdrawal protocol. Other non-drug detoxification methods, additionally, use vitamin therapy (particularly thiamin) and proper nutrition for treating mild withdrawal symptoms.
Special techniques exist for treating alcohol dependency withdrawal. Whereas some of these therapies use medications, scores of, alternatives, do not. Fascinatingly, according to current research findings, the safest way to treat mild withdrawal symptoms is without drugs.
The following epitomizes mild to moderate physical withdrawal symptoms that usually take place within 6 to 48 hours after the last alcoholic drink:
Looking pale
Involuntary movements of the eyelids
Vomiting
Clammy skin
Vomiting
Enlarged or dilated pupils
Nausea
Rapid heart rate
Pulsating headaches
Tremor of the hands
Sweating (especially on the palms of the hands or on the face)
Loss of appetite
Abnormal movements
Sleeping difficulties
More information on alcohol rehab can be found at www.alcholrehab.com.
Article Source: http://EzineArticles.com/?expert=Damian_Murphy
http://EzineArticles.com/?Alcohol-Rehab-Treatment&id=571317
Drug Treatment Runny Nose Specific links
Drug Treatment Runny Nose News
Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying ...
Vertex Pharmaceuticals Incorporated announced today that the European Committee for Medicinal Products for Human Use has issued a positive opinion by consensus recommending the approval of KALYDECO™ for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
Read more...New Phase 3 data for Tradjenta® (linagliptin) tablets in black or African American patients with type 2 diabetes ...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 24, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 ...
Read more...Vivus Announces FDA Approval Of STENDRA™ (avanafil) Tablets For The Treatment Of Erectile Dysfunction
MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- VIVUS, Inc. (VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment ...
Read more...Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion by consensus recommending the approval of KALYDECO ™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator ...
Read more...Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red ...
LANCASTER, Pa. and ROCKVILLE, Md., May 3, 2012 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, ...
Read more...Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in ...
Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO™ that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
Read more...ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of BEPOSONE(TM) Nasal Spray for ...
IRVINE, CA-- - ISTA Pharmaceuticals, Inc. announced today positive results from its Phase 2 randomized, placebo-controlled, parallel-group environmental clinical study of BEPOSONE™ nasal spray for the ...
Read more...The troubled path to painkiller addiction: Prescription drug abuse epidemic taking a toll on Central New York
Many get hooked while using the drugs to treat legitimate pain. Others get addicted after sharing, borrowing or stealing other people's prescription painkillers.
Read more...FDA Approves Vivus's Stendra Tablets To Treat Erectile Dysfunction
FDA Approves Vivus's Stendra Tablets To Treat Erectile Dysfunction
Read more...Allergy sufferers find ways to cope in the great outdoors
York, PA - Joe Stauffer learned to live with them. Meagan Feeser is counting the days until she can make them go away again.
Read more...